|
58
|
204
|
4qlqI |
Ycp in complex with tripeptidic epoxyketone inhibitor 8 |
|
69
|
243
|
4qvyF |
Ycp beta5-a49t-mutant in complex with bortezomib |
|
59
|
196
|
4qwgN |
Ycp beta5-a49v mutant in complex with carfilzomib |
|
69
|
244
|
4qvvB |
Ycp beta5-a49v mutant in complex with bortezomib |
|
73
|
243
|
4qlvF |
Ycp in complex with tripeptidic epoxyketone inhibitor 17 |
|
63
|
241
|
4r02G |
Ycp in complex with bsc4999 (alpha-keto phenylamide) |
|
70
|
212
|
4qw0K |
Ycp beta5-a49t-a50v-double mutant in complex with bortezomib |
|
70
|
242
|
4qv8D |
Ycp beta5-c52f mutant |
|
60
|
222
|
4qv1L |
Ycp beta5-m45a mutant |
|
67
|
242
|
4qwlD |
Ycp beta5-a50v mutant in complex with carfilzomib |
|
56
|
204
|
4qw3I |
Ycp beta5-c63f mutant in complex with bortezomib |
|
61
|
222
|
4qv7L |
Ycp beta5-a50v mutant |
|
71
|
250
|
4r67C |
Human constitutive 20s proteasome in complex with carfilzomib |
|
57
|
204
|
4qvlI |
Ycp in complex with bortezomib |
|
60
|
241
|
4qvvG |
Ycp beta5-a49v mutant in complex with bortezomib |
|
59
|
222
|
4qw5L |
Ycp beta5-m45a mutant in complex with carfilzomib |
|
67
|
250
|
4qvlA |
Ycp in complex with bortezomib |
|
67
|
250
|
4qlqA |
Ycp in complex with tripeptidic epoxyketone inhibitor 8 |
|
68
|
250
|
4qz2A |
Ycp beta5-m45i mutant in complex with the epoxyketone inhibitor onx 0914 |
|
67
|
242
|
4qwjD |
Ycp beta5-a49t-mutant in complex with carfilzomib |
|
65
|
245
|
4r3oG |
Human constitutive 20s proteasome |
|
71
|
243
|
4qz6F |
Ycp beta5-a49t-a50v double mutant in complex with the epoxyketone inhibitor onx 0914 |
|
57
|
204
|
4qz5I |
Ycp beta5-a49t-mutant in complex with onx 0914 |
|
60
|
196
|
4qwjN |
Ycp beta5-a49t-mutant in complex with carfilzomib |
|
57
|
222
|
4qvvL |
Ycp beta5-a49v mutant in complex with bortezomib |
|
68
|
212
|
4qvlK |
Ycp in complex with bortezomib |
|
68
|
233
|
4qluM |
Ycp in complex with tripeptidic epoxyketone inhibitor 9 |
|
72
|
212
|
4qz6K |
Ycp beta5-a49t-a50v double mutant in complex with the epoxyketone inhibitor onx 0914 |
|
61
|
231
|
4qluE |
Ycp in complex with tripeptidic epoxyketone inhibitor 9 |
|
59
|
222
|
4qwfL |
Ycp beta5-m45i mutant in complex with carfilzomib |
|
71
|
233
|
4r18M |
Ligand-induced lys33-thr1 crosslinking at subunit beta5 of the yeast 20s proteasome |
|
59
|
222
|
4qwiL |
Ycp beta5-a49s-mutant in complex with carfilzomib |
|
51
|
199
|
4r670 |
Human constitutive 20s proteasome in complex with carfilzomib |
|
67
|
250
|
4qvwA |
Ycp beta5-a49s-mutant in complex with bortezomib |
|
58
|
196
|
4qw1N |
Ycp beta5-a50v mutant in complex with bortezomib |
|
67
|
233
|
4qv5M |
Ycp beta5-m45i mutant |
|
69
|
250
|
4qluA |
Ycp in complex with tripeptidic epoxyketone inhibitor 9 |
|
69
|
250
|
4qw7A |
Ycp beta5-m45t mutant in complex with carfilzomib |
|
58
|
196
|
4qlvN |
Ycp in complex with tripeptidic epoxyketone inhibitor 17 |
|
60
|
226
|
4r17H |
Ligand-induced aziridine-formation at subunit beta5 of the yeast 20s proteasome |
|
69
|
243
|
4quxF |
Ycp beta5-a49t-mutant |
|
71
|
243
|
4r17F |
Ligand-induced aziridine-formation at subunit beta5 of the yeast 20s proteasome |
|
62
|
241
|
4qwiG |
Ycp beta5-a49s-mutant in complex with carfilzomib |
|
61
|
222
|
4qwuL |
Ycp beta5-c52f mutant in complex with bortezomib |
|
55
|
204
|
4qvmI |
Ycp beta5-m45a mutant in complex with bortezomib |
|
67
|
250
|
4qv4A |
Ycp beta5-m45t mutant |
|
69
|
225
|
4qz5M |
Ycp beta5-a49t-mutant in complex with onx 0914 |
|
66
|
231
|
4qwiE |
Ycp beta5-a49s-mutant in complex with carfilzomib |
|
68
|
242
|
4qw3D |
Ycp beta5-c63f mutant in complex with bortezomib |
|
61
|
196
|
4qv7N |
Ycp beta5-a50v mutant |
